| Bio Roundup: Gilead’s Pionyr Grab, Relay to IPO, Unicorn Sana & More | Sarah de Crescenzo | 06/26/20 | National |
| CSL Behring Bolsters Hemophilia Lineup With Deal for uniQure’s Gene Therapy | Frank Vinluan | 06/25/20 | Philadelphia |
| FDA Official: New “Playbook” Needed for CMC Reviews of Gene Therapy Products | Joanne S. Eglovitch | 06/25/20 | National |
| Relay Lays $200M IPO Plan to Fund Tests of Protein Motion Cancer Drugs | Sarah de Crescenzo | 06/25/20 | Boston |
| La Jolla Pharma Steps In With Better Offer, Wins Tetraphase Bidding War | Frank Vinluan | 06/24/20 | San Diego |
| AsclepiX Emerges With $35M and an Eye Drug Challenger to Eylea, Lucentis | Frank Vinluan | 06/24/20 | National |
| Reneo Readies for Global Test of Drug for Rare Mitochondrial Disease | Sarah de Crescenzo | 06/23/20 | San Diego |
| Gilead Grabs Option to Acquire Pionyr & Its Clinic-Bound Immunotherapies | Sarah de Crescenzo | 06/23/20 | San Francisco |
| Invitae Makes a Precision Oncology Push With $886M Deal for ArcherDx | Frank Vinluan | 06/22/20 | San Francisco |
| Sarepta Inks Codiak Deal to Explore Combining Exosomes, Muscle Meds | Sarah de Crescenzo | 06/22/20 | Boston |
| This Week’s AI & Drug Discovery Conference Xcelerating Life Sciences San Francisco Features insitro, Atomwise, twoXAR, InterVenn, Engine Biosciences & More | Editors | 06/22/20 | National |
| Diversity & Inclusion Events Have Halted. Our Conversations Shouldn’t. | Ramsey Johnson | 06/22/20 | Boston |
| Shattuck Labs Nabs $118M for Cancer Drugs Like Keytruda, But Better | Frank Vinluan | 06/19/20 | Raleigh Durham |
| Timing Is an Essential Element of Cell & Gene Therapy Product Development | Sarah de Crescenzo | 06/19/20 | Philadelphia |
| Bio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More | Frank Vinluan | 06/19/20 | National |
| In Microbiome Milestone, Finch Therapeutics C. diff Pill Bests Placebo | Sarah de Crescenzo | 06/19/20 | Boston |
| Alpine Immune Sciences Lands AbbVie as R&D Partner for Lupus Drug | Frank Vinluan | 06/18/20 | Seattle |
| Engrail Therapeutics Launches With $32M to Develop New Neuro Drugs | Sarah de Crescenzo | 06/18/20 | San Diego |
| Orca Bio Surfaces With $192M and Recipes for “Custom” Cell Therapies | Frank Vinluan | 06/17/20 | San Francisco |
| Frazier Launches Lassen to Advance Antibodies Against Fibrosis, Cancer | Sarah de Crescenzo | 06/17/20 | San Diego |
| C4 Therapeutics Adds $170M to Test Protein Degraders in the Clinic | Sarah de Crescenzo | 06/16/20 | Boston |
| GSK Expands Synthetic Lethality Scope With $120M Ideaya Bio Alliance | Frank Vinluan | 06/16/20 | San Francisco |
| Exec Search Underway at PacBio After CEO, CFO Announce Plans to Retire | Sarah de Crescenzo | 06/16/20 | San Francisco |
| Pharma Partnering: Perspectives from Xcelerating Life Sciences Panel | Frank Vinluan | 06/16/20 | Philadelphia |
| Jazz Pharma Gets Quick FDA OK for New Small Cell Lung Cancer Drug | Sarah de Crescenzo | 06/15/20 | National |
| Akili Interactive’s Video Game for ADHD Gets the FDA All Clear | Frank Vinluan | 06/15/20 | Boston |
| FDA Reverses Authorization for Use of Antimalarials to Treat COVID-19 | Sarah de Crescenzo | 06/15/20 | National |
| GlaxoSmithKline Keeps Oncology 2.0 Growth Plans on Track | Mandy Jackson | 06/12/20 | National |
| Viela Bio Gets FDA Green Light for Rare Autoimmune Disease Treatment | Sarah de Crescenzo | 06/12/20 | National |
| Biotech Roundup: BIO on Racism, AbbVie Antibodies, IPO Surge & More | Sarah de Crescenzo | 06/12/20 | National |
